BLLN · XBRL financial data
BillionToOne financial statements, every fiscal year
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BLLN's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Revenue from contracts with customers | 305,112 |
| Cost of goods and services sold | 96,654 |
| Gross profit | 208,458 |
| Research and development | 49,384 |
| Selling, general and administrative | 143,051 |
| Total operating expenses | 192,435 |
| Operating income (loss) | 16,023 |
| Interest income | 7,750 |
| Interest expense | 95 |
| Other income (expense) | (7,410) |
| Income tax expense (benefit) | 305 |
| Net income (loss) | 7,454 |
| Earnings per share, basic USD per share | 0.18 |
| Earnings per share, diluted USD per share | 0.14 |
| Weighted average shares, basic thousands of shares | 15,875 |
| Weighted average shares, diluted thousands of shares | 21,231 |
Balance sheet
CSVFiscal years (BLLN's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Cash and cash equivalents | 495,975 |
| Accounts receivable | 41,617 |
| Inventory | 17,545 |
| Prepaid and other current assets | 5,421 |
| Total current assets | 560,558 |
| Property and equipment, net | 20,361 |
| Right-of-use asset | 46,742 |
| Total assets | 632,654 |
| Accounts payable | 7,184 |
| Current portion of long-term debt | 0 |
| Total current liabilities | 47,962 |
| Long-term debt | 57,226 |
| Lease liability, non-current | 45,723 |
| Total liabilities | 152,549 |
| Accumulated deficit | (274,747) |
| Total stockholders' equity | 480,105 |
| Total liabilities and equity | 632,654 |
Cash flows
CSVFiscal years (BLLN's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Net income (loss) | 7,454 |
| Stock-based compensation | 15,915 |
| Depreciation and amortization | 6,900 |
| Net cash from operating activities | 24,595 |
| Purchases of property and equipment | 8,881 |
| Net cash from investing activities | (8,922) |
| Share repurchases | 0 |
| Net cash from financing activities | 288,825 |
| Net change in cash | 304,498 |
Compare with peers
SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| BillionToOne | 548,628 | 109,448 | 9,136* | not reported | — | 10-QJun 30, 2026 |
| Castle Biosciences | 62,116 | 103,546 | 15,201* | 30.5M | — | 10-QJun 30, 2026 |
| CareDx | 250,480 | 139,362 | 12,718* | 52.5M | — | 10-QSep 30, 2026 |
| Fulgent Genetics | 26,305 | 85,389 | (23,758)* | 27.5M | 10.8 quarters | 10-QJun 30, 2026 |
| Veracyte | 299,521 | 150,321 | 45,826* | 80.4M | — | 10-QJun 30, 2026 |
| CapForce | 144 | 50,000 | (618)* | 12.4M | 0.2 quarters | 10-QJun 30, 2026 |
| Caris Life Sciences | not reported | 263,712 | 28,477* | 282.6M | — | 10-QJun 30, 2026 |
| Lumexa Imaging Holdings | 69,705 | 264,162 | 32,801* | 96.1M | — | 10-QJun 30, 2026 |
| GRAIL | 55,645 | 44,687 | (80,730)* | 44.7M | 0.7 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.